Opinion
Video
Author(s):
Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.
ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma
Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC
Accurate Diagnosis of dMMR/MSI-H Status Is Key for Nivolumab/Ipilimumab Treatment in mCRC
Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress